Global Information
회사소개 | 문의 | 위시리스트

면역학 관련 각종 제휴 계약 : 계약 조건 및 합의 내용

Global Immunology Partnering 2014-2019: Deal trends, players and financials

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2019년 06월 상품 코드 250302
페이지 정보 영문 400+ Pages
가격
US $ 2,995 ₩ 3,546,000 PDF by E-mail (Single user license)
US $ 4,495 ₩ 5,323,000 PDF by E-mail (Multi user license - 2 to 5 Users)
US $ 8,995 ₩ 10,652,000 PDF by E-mail (Multi User Site License - 6+ Users)
US $ 14,995 ₩ 17,758,000 PDF by E-mail (Global license)


면역학 관련 각종 제휴 계약 : 계약 조건 및 합의 내용 Global Immunology Partnering 2014-2019: Deal trends, players and financials
발행일 : 2019년 06월 페이지 정보 : 영문 400+ Pages

2007년 이후의 면역학(Immunology) 관련 각종 제휴 계약에 대해 조사 분석하고, 최근 각종 계약 동향, 대규모 계약 및 대형 제약회사의 계약 개요, 계약 구분·개발 단계·기술 구분·적응증 구분별 디렉토리 등의 정보를 전해드립니다.

주요 요약

제1장 서론

제2장 면역학 관련 각종 계약 동향

  • 서론
  • 과거 수년간 면역학 관련 제휴
  • 대형 제약회사의 계약 활동
  • 면역학 관련 사업에 적극적이지 않은 대형 제약회사
  • 면역학 관련 제휴 : 계약 종류별
  • 면역학 관련 제휴 : 산업 부문별
  • 면역학 관련 제휴 : 개발 단계별
  • 면역학 관련 제휴 : 기술 종류별
  • 면역학 관련 제휴 : 적응증별
  • 평균 계약 기간

제3장 주요 계약

  • 서론
  • 주요 계약 : 거래액별
  • 대형 제약회사와 관계된 주요 계약

제4장 대형 제약회사의 계약

  • 서론
  • 대형 제약회사의 제휴 계약 이용법
  • 기업 개요

제5장 계약 디렉토리

  • 서론
  • 계약 종류별
    • 자산 구입
    • 양도
    • 대형 제약회사의 아웃라이선싱
    • 공동 개발
    • 공동 R&D
    • 공동 판매
    • 서비스 계약
    • 공동 프로모션
    • 크로스 라이선싱
    • 유통
    • 주식 구입
    • 합작투자
    • 라이선싱
    • 소송
    • 대출
    • 제조
    • 마케팅
    • 옵션
    • 프로모션
    • 연구
    • 타결 관련
    • 스핀아웃
    • 서브 라이선스
    • 공급
    • 종료
  • 개발 단계별
    • 디스커버리
    • 제제
    • 단계 I
    • 단계 II
    • 단계 III
    • 전임상
    • 규제
  • 기술 종류별
    • 항체
    • 어세이
    • 생물학적 화합물
    • 세포 치료
    • 기기
    • 디스커버리 툴
    • 실현 기술
    • 설비
    • 장비
    • 게노믹스
    • 인비트로 모델
    • 천연 제품
    • 올리고뉴클레오티드
    • 희귀의약품
    • 포장
    • 펩티드
    • 가공
    • 프로테오믹스
    • 재편성 DNA
    • RNA 치료
    • 스크리닝
    • 저분자
    • 줄기세포
    • 백신

제6장 면역학 관련 계약 : 적응증별

  • 서론
  • 적응증별
    • 면역학
    • AIDS
    • 알레르기
    • 과민성 쇼크
    • 이식편대 숙주질환(GVHD)
    • 염증
    • 전신성 홍반성 루푸스(SLE)
    • 경피증

제7장 제휴 기회

  • 온라인 파트너링
  • 파트너링 이벤트
  • 관련 자료

부록

도표

KSM 12.09.18

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

‘The Global Immunology Partnering 2014-2019: Deal trends, players and financials report ’ provides comprehensive understanding and unprecedented access to the immunology/autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies.

‘Global Immunology Partnering 2014 to 2019 ’ provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

  • Trends in Immunology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Immunology partnering agreement structure
  • Immunology partnering contract documents
  • Top Immunology deals by value
  • Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2014. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope

‘Global Immunology Partnering 2014 to 2019’ is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

‘Global Immunology Partnering 2014 to 2019’ includes:

  • Trends in Immunology dealmaking in the biopharma industry since 2014
  • Analysis of Immunology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Immunology deal contract documents
  • Comprehensive access to over 540 Immunology deal records
  • The leading Immunology deals by value since 2014
  • Most active Immunology dealmakers since 2014

The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In ‘Global Immunology Partnering 2014 to 2019’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

‘The Global Immunology Partnering 2014-2019 report ’ provides comprehensive access to available deals and contract documents for over 540 immunology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Immunology Partnering 2014 to 2019 ’ provides the reader with the following key benefits:

  • In-depth understanding of Immunology deal trends since 2014
  • Access Immunology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Immunology partner companies
  • Comprehensive access to over 540 links to actual Immunology deals entered into by the world's biopharma companies
  • Indepth review of Immunology deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Immunology opportunities
  • Uncover companies actively partnering Immunology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Immunology dealmaking

  • 2.1. Introduction
  • 2.2. Immunology partnering over the years
  • 2.3. Immunology partnering by deal type
  • 2.4. Immunology partnering by industry sector
  • 2.5. Immunology partnering by stage of development
  • 2.6. Immunology partnering by technology type
  • 2.7. Immunology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Immunology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Immunology partnering
  • 3.3. Immunology partnering headline values
  • 3.4. Immunology deal upfront payments
  • 3.5. Immunology deal milestone payments
  • 3.6. Immunology royalty rates

Chapter 4 - Leading Immunology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Immunology partnering
  • 4.3. List of most active dealmakers in Immunology
  • 4.4. Top Immunology deals by value

Chapter 5 - Immunology contract document directory

  • 5.1. Introduction
  • 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Immunology therapeutic target

Appendices

  • Appendix 1 - Directory of Immunology deals by company A-Z 2014 to 2019
  • Appendix 2 - Directory of Immunology deals by deal type 2014 to 2019
  • Appendix 3 - Directory of Immunology deals by stage of development 2014 to 2019
  • Appendix 4 - Directory of Immunology deals by technology type 2014 to 2019
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Immunology partnering since 2014
  • Figure 2: Immunology partnering by deal type since 2014
  • Figure 3: Immunology partnering by industry sector since 2014
  • Figure 4: Immunology partnering by stage of development since 2014
  • Figure 5: Immunology partnering by technology type since 2014
  • Figure 6: Immunology partnering by indication since 2014
  • Figure 7: Immunology deals with a headline value
  • Figure 8: Immunology deals with upfront payment values
  • Figure 9: Immunology deals with milestone payment
  • Figure 10: Immunology deals with royalty rates
  • Figure 11: Active Immunology dealmaking activity- 2014 to 2019
  • Figure 12: Top Immunology deals by value since 2014
Back to Top
전화 문의
F A Q